Abstract
The biopharmaceutical properties of doxorubicin delivered via two drug-delivery systems (DDSs) for the palliative treatment of unresectable hepatocellular carcinoma were reviewed with relation to the associated liver and tumor (patho)physiology. These two DDSs, doxorubicin emulsified with Lipiodol(®) and doxorubicin loaded into DC Bead(®) are different regarding tumor delivery, release rate, local bioavailability, if and how they can be given repeatedly, biodegradability, length of embolization and safety profile. There have been few direct head-to-head comparisons of these DDSs, and in-depth investigations into their in vitro and in vivo performance is warranted.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antibiotics, Antineoplastic / administration & dosage*
-
Antibiotics, Antineoplastic / chemistry
-
Antibiotics, Antineoplastic / metabolism
-
Antibiotics, Antineoplastic / pharmacokinetics
-
Biological Availability
-
Carcinoma, Hepatocellular / drug therapy*
-
Carcinoma, Hepatocellular / metabolism
-
Carcinoma, Hepatocellular / pathology
-
Doxorubicin / administration & dosage*
-
Doxorubicin / chemistry
-
Doxorubicin / metabolism
-
Doxorubicin / pharmacokinetics
-
Drug Carriers*
-
Drug Stability
-
Ethiodized Oil / chemistry*
-
Humans
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / metabolism
-
Liver Neoplasms / pathology
-
Neoplasm Staging
-
Polyvinyl Alcohol / chemistry*
-
Solubility
-
Tissue Distribution
Substances
-
Antibiotics, Antineoplastic
-
Drug Carriers
-
polyvinyl alcohol hydrogel
-
Ethiodized Oil
-
Doxorubicin
-
Polyvinyl Alcohol